Baystreet.ca News Commentary – In the United States, federal budget cuts threaten to slow the nation’s progress in the fight against cancer, but the private sector appears ...

Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.

Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.

FDA approval of IBTROZI (taletrectinib) transformed Nuvation Bio into a commercial-stage company, driving $4.8 million in GAAP revenue, well above GAAP revenue estimates. Earnings per share (GAAP) was ...

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +93.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the IASLC 2025 ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the penny stocks that will skyrocket. On June 24, the company confirmed the addition of its Taletrectinib (IBTROZI) treatment as a Preferred Agent in the ...

Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer ...

Shares of Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) have been assigned an average rating of “Buy” from the six analysts that are presently covering the company, MarketBeat reports ...